Obesity Drugs: New Guidance Supports Long-Term Use & Informed Choice

Obesity Treatment: New Guidance Highlights Drug Effectiveness and Reframes Care

Recent joint guidance from leading obesity organizations affirms the effectiveness and safety of weight-loss drugs for long-term use, potentially reshaping how clinicians approach the chronic disease. The recommendations, published in Obesity Pillars and Obesity, emphasize that medications can play a critical role in improving both health and quality of life, and signal a shift toward recognizing obesity as a complex medical condition rather than a matter of willpower. This comes alongside approvals of highly-effective obesity medications, prompting an update to existing guidelines.

A Chronic Disease, Not a Personal Failing

For years, obesity has been stigmatized as a personal failing, often attributed to a lack of discipline or poor lifestyle choices. However, the new guidance reinforces the scientific understanding of obesity as a chronic medical condition rooted in biological factors. This reframing is crucial, experts say, as it encourages a more compassionate and effective approach to treatment. The guidance specifically recommends continuing weight-loss drugs even during weight maintenance phases, acknowledging the chronic nature of the condition.

Which Medications are Recommended?

The guidance provides strong recommendations for several drugs currently available, including semaglutide (Wegovy/Ozempic, Novo Nordisk), setmelanotide (Imcivree, Rhythm Pharmaceuticals), bupropion/naltrexone (Contrave, Currax Pharmaceuticals), and tirzepatide (Zepbound, Eli Lilly). These medications function through different mechanisms to help individuals achieve and maintain weight loss, and are often used in conjunction with lifestyle modifications like diet and exercise. The recent FDA approval of an oral formulation of semaglutide further expands treatment options.

Informed Discussions and Realistic Goals

Jonathan Q. Purnell, MD, FTOS, vice president of The Obesity Society and coauthor of the guidance, emphasized the importance of informed discussions between physicians and patients. “Having an informed discussion includes counseling that these are long-term therapies, establishing desirable goals for weight loss and meaningful improvements in obesity complications, using medications that have specific indications for identified obesity complications, and preparing for potential gastrointestinal side effects that limit tolerability or necessitate switching to a different medication,” he explained. Setting realistic expectations and addressing potential side effects proactively can improve patient adherence and overall treatment success.

Insurance Coverage Challenges and Alternative Treatments

Despite the growing evidence supporting the use of weight-loss medications, access to these treatments remains a significant barrier for many individuals. Reports indicate that some health insurers are dropping coverage for GLP-1 receptor agonists for weight loss alone, raising concerns about health inequities. Purnell argues that denying coverage for these medications is counterproductive, comparing it to delaying diabetes treatment until complications arise.

For patients facing coverage limitations or who are unable to tolerate GLP-1 receptor agonists, alternative treatments are available. However, Purnell notes that non-GLP-1 medications generally have reduced weight loss efficacy and less robust data on long-term safety and outcomes. Choosing the right medication requires careful consideration of individual patient factors and potential benefits and risks.

Destigmatizing Obesity Treatment

The increasing attention surrounding GLP-1 receptor agonists may be helping to destigmatize obesity treatment, both among patients and physicians. Purnell hopes that the success of these medications will encourage practitioners to view weight regulation as a biological process, rather than a matter of willpower. “This will take confronting our own implicit biases, engaging in continuing medical education to become more familiar with the biology and outcomes data, and then engaging with the patient to initiate therapy to gain experience and comfort with their use,” he said.

Key Takeaways for Primary Care Physicians

Purnell highlighted three key messages for primary care physicians: obesity is a chronic medical condition, pharmacologic therapies are available, and weight reduction is only one aspect of obesity treatment – improvements in quality of life and management of obesity-related complications are equally important. Future advancements in obesity pharmacotherapy are also anticipated, offering even more options for patients.

Looking Ahead: The Supreme Court of Georgia issued an email scam alert on January 22, 2026, warning the public about fraudulent emails impersonating court staff. This serves as a reminder to be vigilant about online security and to verify any unsolicited communications claiming to be from official sources. This represents unrelated to the obesity guidance, but highlights the importance of verifying information in the digital age.

Contact Information: Jonathan Q. Purnell, MD, FTOS, can be reached through Meghan Tisinger, managing director of Leidar USA, at [email protected].